Credit Suisse analyst Evan Seigerman lowered the firm's price target on Aimmune to $29 from $34 and keeps a Neutral rating on the shares. Following last month's approval of Palforzia, Aimmune provided incremental color on the launch progress of Palforzia, saying that substantial sales are unlikely in Q1. While the analyst initially forecasted a very modest $2M in Q1 sales, recent commentary from the company suggests that FDA has not yet released the initial lots to the commercial market. Seigerman thinks this combined with a REMS program that was not operational until last week, points to limited Q1 sales.